Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis

Next Previous
X
Search
Trial Profile

A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MIV 711 (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Medivir AB

    • Most Recent Events

    • 28 Feb 2022 According to a Medivir AB media release, post-hoc analysis of a randomised phase 2a clinical trial has been published in the Clinical and Experimental Rheumatology 2022.
    • 25 Feb 2022 Results of post-hoc analysis assessing symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain, published in the Clinical and Experimental Rheumatology.
    • 31 Dec 2019 Results of randomized, double-blind, placebo-controlled phase 2a study with open-label safety extension substudy assessing Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis has been published in the Annals of Internal Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top